Klotho Neurosciences Inc(KLTO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.33 | Insider Own | 10.53% | Shs Outstand | 70.3M | Perf Week | 27.05% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 65.8M | Perf Month | 117.51% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 6.04% | Short Float | 3.35% | Perf Quarter | 16.36% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 5.23% | Short Ratio | 0.71 | Perf Half Y | -2.55% |
| Sales | 0.00B | P/B | 3.71 | EPS next 5Y | - | ROA | -180.1% | Short Interest | 2.20M | Perf YTD | 81.38% |
| Book/sh | 0.14 | P/C | 5.24 | EPS past 3/5Y | -921.21% - | ROE | -198.28% | 52W High | -86.59% ($3.91) | Perf Year | 85.36% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -113.73% | 52W Low | 361.85% ($0.11) | Perf 3Y | -94.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -53.57% | Gross Margin | - | Volatility(W/M) | 34.69% 25.67% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 83.69 | EPS Q/Q | 72.53% | Profit Margin | - | RSI (14) | 61.91 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 83.69 | Sales Q/Q | - | SMA20 | 34.32% ($0.39) | Beta | 2.24 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 55.99% ($0.33) | Rel Volume | 0.73 | Prev Close | $0.52 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -16.8% ($0.63) | Avg Volume(3M) | 3.12M | Price | $0.52 |
| IPO | 2022/4/29 | Option/Short | No/Yes | Trades | 2553 | Volume | 2,267,463 | Change | 0.81% |
🔬 Klotho Neurosciences (KLTO) is a biotech venture developing regenerative medicine and gene therapeutics based on the Klotho protein to treat Alzheimer's, Parkinson's disease, and other age-related degenerative neurological disorders.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
KLTO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -94.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.0%.
Tap to view numbers
It ranks #435 of 595 in the industry
Based on market cap of $39M.
ALDX#434 Aldeyra Therapeutics Inc $39M PER - KLTO#435 Klotho Neurosciences Inc $39M PER - 
GRCE#435 Grace Therapeutics Inc $38M PER - 
TIL#436 Instil Bio Inc $38M PER - 
DWTX#437 Dogwood Therapeutics Inc $38M PER - 
FAQ
What kind of company is KLTO?
KLTO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KLTO?
The market cap of KLTO is approximately $39M, ranking 5,006 within its sector.
What is the 52-week high and low for KLTO?
KLTO has recorded a 52-week high of $3.91 and a low of $0.11.
